Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Diabetes

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 198 articles:
HTML format



Single Articles


    June 2021
  1. GERSTEIN HC, Sattar N, Rosenstock J, Ramasundarahettige C, et al
    Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.
    N Engl J Med. 2021 Jun 28. doi: 10.1056/NEJMoa2108269.
    PubMed     Abstract available


  2. FRIAS JP, Davies MJ, Rosenstock J, Perez Manghi FC, et al
    Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    N Engl J Med. 2021 Jun 25. doi: 10.1056/NEJMoa2107519.
    PubMed     Abstract available


  3. TUTTLE KR
    Breaking New Ground with Incretin Therapy in Diabetes.
    N Engl J Med. 2021 Jun 25. doi: 10.1056/NEJMe2109957.
    PubMed    


  4. FANG M, Wang D, Coresh J, Selvin E, et al
    Trends in Diabetes Treatment and Control in U.S. Adults, 1999-2018.
    N Engl J Med. 2021;384:2219-2228.
    PubMed     Abstract available


    May 2021
  5. YEKU OO, Medford AJ, Fenves AZ, Uljon SN, et al
    Case 15-2021: A 76-Year-Old Woman with Nausea, Diarrhea, and Acute Kidney Failure.
    N Engl J Med. 2021;384:1943-1950.
    PubMed    


  6. GOYAL RK
    Gastric Emptying Abnormalities in Diabetes Mellitus.
    N Engl J Med. 2021;384:1742-1751.
    PubMed    


    April 2021
  7. BHATT DL, Steg PG, Pitt B
    Cardiovascular Outcomes with Sotagliflozin. Reply.
    N Engl J Med. 2021;384:1471-1473.
    PubMed    


  8. MARCHAND L, Villar E, Green L
    Cardiovascular Outcomes with Sotagliflozin.
    N Engl J Med. 2021;384:1471.
    PubMed    


  9. BAGLIONI P
    Cardiovascular Outcomes with Sotagliflozin.
    N Engl J Med. 2021;384:1470-1471.
    PubMed    


  10. KALYANI RR
    Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes.
    N Engl J Med. 2021;384:1248-1260.
    PubMed    


  11. MINTER DJ, Richie M, Kumthekar P, Hollander H, et al
    Stalking the Diagnosis.
    N Engl J Med. 2021;384:1262-1267.
    PubMed    


    March 2021
  12. BAKRIS GL, Agarwal R, Filippatos G
    Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes. Reply.
    N Engl J Med. 2021;384:e42.
    PubMed    


  13. MOURA-NETO JA, Ronco C
    Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes.
    N Engl J Med. 2021;384:e42.
    PubMed    


  14. YOUNG MJ, Fuller PJ
    Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes.
    N Engl J Med. 2021;384:e42.
    PubMed    


  15. EDWARDS NC, Ferro CJ, Townend JN
    Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes.
    N Engl J Med. 2021;384:e42.
    PubMed    


  16. MAKEMBI AB, Mohamadou I, Galichon P
    Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes.
    N Engl J Med. 2021;384:e42.
    PubMed    


  17. BAUMSTEIN D
    Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes.
    N Engl J Med. 2021;384:e42.
    PubMed    


  18. CACOUB P, Saadoun D
    Extrahepatic Manifestations of Chronic HCV Infection.
    N Engl J Med. 2021;384:1038-1052.
    PubMed    


  19. CASEY B
    Gestational Diabetes - On Broadening the Diagnosis.
    N Engl J Med. 2021;384:965-966.
    PubMed    


  20. HILLIER TA, Pedula KL, Ogasawara KK, Vesco KK, et al
    A Pragmatic, Randomized Clinical Trial of Gestational Diabetes Screening.
    N Engl J Med. 2021;384:895-904.
    PubMed     Abstract available


  21. BUTLER PC
    Supplying Insulin while Evading Immunity.
    N Engl J Med. 2021;384:967-969.
    PubMed    


    February 2021
  22. ROSENSTOCK J, Hansen MV, Goldenberg R
    Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. Reply.
    N Engl J Med. 2021;384:e26.
    PubMed    


  23. SHAH VN
    Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.
    N Engl J Med. 2021;384:e26.
    PubMed    


  24. SUZUKI Y, Zhao T, Tsubokura M
    Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.
    N Engl J Med. 2021;384:e26.
    PubMed    


  25. WILDING JPH, Batterham RL, Calanna S, Davies M, et al
    Once-Weekly Semaglutide in Adults with Overweight or Obesity.
    N Engl J Med. 2021 Feb 10. doi: 10.1056/NEJMoa2032183.
    PubMed     Abstract available


    January 2021
  26. BROSIUS FC, Vandvik PO
    Cardioprotection with Yet Another SGLT2 Inhibitor - An Embarrassment of Riches.
    N Engl J Med. 2021;384:179-181.
    PubMed    


  27. ANDERSON MS, Chaimowitz NS, Forbes LR
    More on STAT1 Gain of Function, Type 1 Diabetes, and JAK Inhibition. Reply.
    N Engl J Med. 2021;384:93-94.
    PubMed    


  28. JOHNSON MB, Hattersley AT, Patel KA
    More on STAT1 Gain of Function, Type 1 Diabetes, and JAK Inhibition.
    N Engl J Med. 2021;384:93.
    PubMed    


    December 2020
  29. BRETON MD, Beck RW, Wadwa RP
    A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes. Reply.
    N Engl J Med. 2020;383:2484.
    PubMed    


  30. FERNANDES N
    A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes.
    N Engl J Med. 2020;383:2484.
    PubMed    


  31. YOSHINO M, Kayser BD, Klein S
    Effect of Diet versus Gastric Bypass on Metabolic Function in Diabetes. Reply.
    N Engl J Med. 2020;383:2393-2394.
    PubMed    


  32. CASTAGNETO-GISSEY L, Casella G, Mingrone G
    Effect of Diet versus Gastric Bypass on Metabolic Function in Diabetes.
    N Engl J Med. 2020;383:2392-2393.
    PubMed    


  33. SAEIDI N, Stefater M, Stylopoulos N
    Effect of Diet versus Gastric Bypass on Metabolic Function in Diabetes.
    N Engl J Med. 2020;383:2391-2392.
    PubMed    


  34. ABU DAYYEH BK
    Effect of Diet versus Gastric Bypass on Metabolic Function in Diabetes.
    N Engl J Med. 2020;383:2391.
    PubMed    


  35. RUBINO F, Cohen RV
    Effect of Diet versus Gastric Bypass on Metabolic Function in Diabetes.
    N Engl J Med. 2020;383:2390-2391.
    PubMed    


  36. BAKRIS GL, Agarwal R, Anker SD, Pitt B, et al
    Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
    N Engl J Med. 2020;383:2219-2229.
    PubMed     Abstract available


    November 2020
  37. GOTTLIEB PA, Michels AW
    Advances in Diabetes Treatment - Once-Weekly Insulin.
    N Engl J Med. 2020;383:2171-2172.
    PubMed    


  38. ACCILI D
    Whither Type 1 Diabetes?
    N Engl J Med. 2020;383:2078-2079.
    PubMed    


  39. QUATTRIN T, Haller MJ, Steck AK, Felner EI, et al
    Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes.
    N Engl J Med. 2020;383:2007-2017.
    PubMed     Abstract available


  40. BHATT DL, Szarek M, Steg PG, Cannon CP, et al
    Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
    N Engl J Med. 2020 Nov 16. doi: 10.1056/NEJMoa2030183.
    PubMed     Abstract available


  41. BHATT DL, Szarek M, Pitt B, Cannon CP, et al
    Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
    N Engl J Med. 2020 Nov 16. doi: 10.1056/NEJMoa2030186.
    PubMed     Abstract available


  42. NEWSOME PN, Buchholtz K, Cusi K, Linder M, et al
    A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
    N Engl J Med. 2020 Nov 13. doi: 10.1056/NEJMoa2028395.
    PubMed     Abstract available


  43. CAPLAN DN, Rapalino O, Karaa A, Rosovsky RP, et al
    Case 35-2020: A 59-Year-Old Woman with Type 1 Diabetes Mellitus and Obtundation.
    N Engl J Med. 2020;383:1974-1983.
    PubMed    


    October 2020
  44. INGELFINGER JR, Rosen CJ
    Finerenone - Halting Relative Hyperaldosteronism in Chronic Kidney Disease.
    N Engl J Med. 2020 Oct 23. doi: 10.1056/NEJMe2031382.
    PubMed    


  45. FERNANDEZ-PRADO R, Ortiz A, Perez-Gomez MV
    Allopurinol and Chronic Kidney Disease.
    N Engl J Med. 2020;383:1690.
    PubMed    


  46. MCCORMICK N, Zhang Y, Choi HK
    Allopurinol and Chronic Kidney Disease.
    N Engl J Med. 2020;383:1689-1690.
    PubMed    


  47. CONWAY R
    Allopurinol and Chronic Kidney Disease.
    N Engl J Med. 2020;383:1689.
    PubMed    


  48. PONTICELLI C, Podesta MA
    Allopurinol and Chronic Kidney Disease.
    N Engl J Med. 2020;383:1688-1689.
    PubMed    


  49. KANG DH, Sanchez-Lozada LG, Johnson RJ
    Allopurinol and Chronic Kidney Disease.
    N Engl J Med. 2020;383:1687-1688.
    PubMed    


  50. CHAIMOWITZ NS, Ebenezer SJ, Hanson IC, Anderson M, et al
    STAT1 Gain of Function, Type 1 Diabetes, and Reversal with JAK Inhibition.
    N Engl J Med. 2020;383:1494-1496.
    PubMed    


    September 2020
  51. HEERSPINK HJL, Stefansson BV, Correa-Rotter R, Chertow GM, et al
    Dapagliflozin in Patients with Chronic Kidney Disease.
    N Engl J Med. 2020 Sep 24. doi: 10.1056/NEJMoa2024816.
    PubMed     Abstract available


  52. CHONG WH, Yanoff LB, Andraca-Carrera E, Thanh Hai M, et al
    Assessing the Safety of Glucose-Lowering Drugs - A New Focus for the FDA.
    N Engl J Med. 2020;383:1199-1202.
    PubMed    


  53. CANNON CP, Pratley R, Dagogo-Jack S, Mancuso J, et al
    Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
    N Engl J Med. 2020 Sep 23. doi: 10.1056/NEJMoa2004967.
    PubMed     Abstract available


  54. ROSENSTOCK J, Bajaj HS, Janez A, Silver R, et al
    Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.
    N Engl J Med. 2020 Sep 22. doi: 10.1056/NEJMoa2022474.
    PubMed     Abstract available


    August 2020
  55. PACKER M, Anker SD, Butler J, Filippatos G, et al
    Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
    N Engl J Med. 2020 Aug 29. doi: 10.1056/NEJMoa2022190.
    PubMed     Abstract available


  56. BRETON MD, Kanapka LG, Beck RW, Ekhlaspour L, et al
    A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes.
    N Engl J Med. 2020;383:836-845.
    PubMed     Abstract available


  57. YOSHINO M, Kayser BD, Yoshino J, Stein RI, et al
    Effects of Diet versus Gastric Bypass on Metabolic Function in Diabetes.
    N Engl J Med. 2020;383:721-732.
    PubMed     Abstract available


  58. ROSEN CJ, Ingelfinger JR
    Bariatric Surgery and Restoration of Insulin Sensitivity - It's Weight Loss.
    N Engl J Med. 2020;383:777-778.
    PubMed    


  59. SINGHAL AB, Gonzalez RG, Chwalisz BK, Mukerji SS, et al
    Case 26-2020: A 60-Year-Old Woman with Altered Mental Status and Weakness on the Left Side.
    N Engl J Med. 2020;383:764-773.
    PubMed    


  60. BANERJEE A, Shah SR
    Necrolytic Migratory Erythema Associated with a Glucagonoma.
    N Engl J Med. 2020;383:e39.
    PubMed    


    July 2020
  61. JAMPOL LM, Glassman AR, Sun JK
    Evaluation and Care of Patients with Diabetic Retinopathy. Reply.
    N Engl J Med. 2020;383:e31.
    PubMed    


  62. PARMAR MS
    Evaluation and Care of Patients with Diabetic Retinopathy.
    N Engl J Med. 2020;383:e31.
    PubMed    


  63. NASHAWI M
    Evaluation and Care of Patients with Diabetic Retinopathy.
    N Engl J Med. 2020;383:e31.
    PubMed    


  64. FOLK JC, Abramoff MD
    Evaluation and Care of Patients with Diabetic Retinopathy.
    N Engl J Med. 2020;383:e31.
    PubMed    


  65. VAN DAM RM, Hu FB, Willett WC
    Coffee, Caffeine, and Health.
    N Engl J Med. 2020;383:369-378.
    PubMed    


  66. NISHIOKA R, Kawano M
    Tongue Ulceration from Cytomegalovirus Infection.
    N Engl J Med. 2020;383:67.
    PubMed    


  67. GAY E
    Blame.
    N Engl J Med. 2020;383:9.
    PubMed    


    June 2020
  68. FEIG DI
    Urate-Lowering Therapy and Chronic Kidney Disease Progression.
    N Engl J Med. 2020;382:2567-2568.
    PubMed    


  69. DORIA A, Galecki AT, Spino C, Pop-Busui R, et al
    Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes.
    N Engl J Med. 2020;382:2493-2503.
    PubMed     Abstract available


  70. BADVE SV, Pascoe EM, Tiku A, Boudville N, et al
    Effects of Allopurinol on the Progression of Chronic Kidney Disease.
    N Engl J Med. 2020;382:2504-2513.
    PubMed     Abstract available


  71. RUBINO F, Amiel SA, Zimmet P, Alberti G, et al
    New-Onset Diabetes in Covid-19.
    N Engl J Med. 2020 Jun 12. doi: 10.1056/NEJMc2018688.
    PubMed    


    April 2020
  72. OXLEY TJ, Mocco J, Majidi S, Kellner CP, et al
    Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young.
    N Engl J Med. 2020 Apr 28. doi: 10.1056/NEJMc2009787.
    PubMed    


  73. JAMPOL LM, Glassman AR, Sun J
    Evaluation and Care of Patients with Diabetic Retinopathy.
    N Engl J Med. 2020;382:1629-1637.
    PubMed    


    March 2020
  74. SOCAL MP, Greene JA
    Interchangeable Insulins - New Pathways for Safe, Effective, Affordable Diabetes Therapy.
    N Engl J Med. 2020;382:981-983.
    PubMed    


    February 2020
  75. UDLER MS, Powe CE, Austin-Tse CA
    Case 6-2020: A 34-Year-Old Woman with Hyperglycemia.
    N Engl J Med. 2020;382:745-753.
    PubMed    



  76. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
    N Engl J Med. 2020;382:586.
    PubMed    


  77. KOVATCHEV BP, Brown SA, Beck RW
    Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. Reply.
    N Engl J Med. 2020;382:578.
    PubMed    


  78. ZUNIGA-HERNANDEZ JA, Medrano-De Avila C, Rodriguez-Gutierrez R
    Multicenter Trial of Closed-Loop Control in Type 1 Diabetes.
    N Engl J Med. 2020;382:577-578.
    PubMed    


  79. TAKITA M
    Multicenter Trial of Closed-Loop Control in Type 1 Diabetes.
    N Engl J Med. 2020;382:577.
    PubMed    


    December 2019
  80. DE CABO R, Mattson MP
    Effects of Intermittent Fasting on Health, Aging, and Disease.
    N Engl J Med. 2019;381:2541-2551.
    PubMed    


  81. ARANY Z
    Taking a BAT to the Chains of Diabetes.
    N Engl J Med. 2019;381:2270-2272.
    PubMed    


    November 2019
  82. HUSAIN M, Donsmark M, Bain SC
    Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes. Reply.
    N Engl J Med. 2019;381:2076-2077.
    PubMed    


  83. ZWECK E, Westenfeld R, Szendroedi J
    Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2019;381:2075-2076.
    PubMed    


  84. HEROLD KC, Bundy BN, Krischer JP
    Teplizumab in Relatives at Risk for Type 1 Diabetes. Reply.
    N Engl J Med. 2019;381:1880-1881.
    PubMed    


  85. KORSGREN O, Skog O, Ludvigsson J
    Teplizumab in Relatives at Risk for Type 1 Diabetes.
    N Engl J Med. 2019;381:1879-1880.
    PubMed    


  86. COURI CE, Malmegrim KCR, Oliveira MC
    Teplizumab in Relatives at Risk for Type 1 Diabetes.
    N Engl J Med. 2019;381:1879.
    PubMed    


  87. ILANY J
    Teplizumab in Relatives at Risk for Type 1 Diabetes.
    N Engl J Med. 2019;381:1879.
    PubMed    


    October 2019
  88. TAMBORLANE WV, Fainberg U, Barrett T
    Liraglutide in Children and Teens with Type 2 Diabetes. Reply.
    N Engl J Med. 2019;381:1787.
    PubMed    


  89. JAVOR E, Skelin M, Lucijanic M
    Liraglutide in Children and Teens with Type 2 Diabetes.
    N Engl J Med. 2019;381:1786-1787.
    PubMed    


  90. PITTAS A, Dawson-Hughes B, Staten M
    Vitamin D Supplementation and Prevention of Type 2 Diabetes. Reply.
    N Engl J Med. 2019;381:1785-1786.
    PubMed    


  91. MANSUR JL
    Vitamin D Supplementation and Prevention of Type 2 Diabetes.
    N Engl J Med. 2019;381:1785.
    PubMed    


  92. HASSAN-SMITH Z, Hewison M, Gittoes N
    Vitamin D Supplementation and Prevention of Type 2 Diabetes.
    N Engl J Med. 2019;381:1784-1785.
    PubMed    


  93. AKTAS BY, Ozturk Aktas O
    Vitamin D Supplementation and Prevention of Type 2 Diabetes.
    N Engl J Med. 2019;381:1784.
    PubMed    


  94. BRUTTOMESSO D
    Toward Automated Insulin Delivery.
    N Engl J Med. 2019;381:1774-1775.
    PubMed    



  95. Electrolyte and Acid-Base Disturbances in Patients with Diabetes Mellitus.
    N Engl J Med. 2019;381:1598.
    PubMed    


  96. BROWN SA, Kovatchev BP, Raghinaru D, Lum JW, et al
    Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes.
    N Engl J Med. 2019 Oct 16. doi: 10.1056/NEJMoa1907863.
    PubMed     Abstract available


    September 2019
  97. REAVEN PD, Hayward RA, Zhou J
    Intensive Glucose Control and Type 2 Diabetes - 15 Years On. Reply.
    N Engl J Med. 2019;381:1293.
    PubMed    


  98. CERIELLO A, Nicolucci A
    Intensive Glucose Control and Type 2 Diabetes - 15 Years On.
    N Engl J Med. 2019;381:1292-1293.
    PubMed    


  99. MCMURRAY JJV, Solomon SD, Inzucchi SE, Kober L, et al
    Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
    N Engl J Med. 2019 Sep 19. doi: 10.1056/NEJMoa1911303.
    PubMed     Abstract available


  100. JARDINE MJ, Mahaffey KW, Perkovic V
    Canagliflozin and Renal Outcomes in Diabetic Nephropathy. Reply.
    N Engl J Med. 2019;381:1089-1090.
    PubMed    


  101. POST A, Eisenga MF, Bakker SJL
    Canagliflozin and Renal Outcomes in Diabetic Nephropathy.
    N Engl J Med. 2019;381:1089.
    PubMed    


  102. LIMA JG, Santos MC, Simas BC
    Canagliflozin and Renal Outcomes in Diabetic Nephropathy.
    N Engl J Med. 2019;381:1088-1089.
    PubMed    


  103. ISREB M, Al-Makki A, Buatois E
    Canagliflozin and Renal Outcomes in Diabetic Nephropathy.
    N Engl J Med. 2019;381:1088.
    PubMed    


  104. LESLIE BR, Gerwin LE
    Canagliflozin and Renal Outcomes in Diabetic Nephropathy.
    N Engl J Med. 2019;381:1087-1088.
    PubMed    


  105. MAKRIDES M, Best K, Yelland L, McPhee A, et al
    A Randomized Trial of Prenatal n-3 Fatty Acid Supplementation and Preterm Delivery.
    N Engl J Med. 2019;381:1035-1045.
    PubMed     Abstract available


  106. STEG PG, Bhatt DL, Simon T, Fox K, et al
    Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
    N Engl J Med. 2019 Sep 1. doi: 10.1056/NEJMoa1908077.
    PubMed     Abstract available


  107. BATES ER
    Antiplatelet Therapy in Patients with Coronary Disease and Type 2 Diabetes.
    N Engl J Med. 2019 Sep 1. doi: 10.1056/NEJMe1910813.
    PubMed    


    June 2019
  108. HUSAIN M, Birkenfeld AL, Donsmark M, Dungan K, et al
    Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
    N Engl J Med. 2019 Jun 11. doi: 10.1056/NEJMoa1901118.
    PubMed     Abstract available


  109. HEROLD KC, Bundy BN, Long SA, Bluestone JA, et al
    An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
    N Engl J Med. 2019 Jun 9. doi: 10.1056/NEJMoa1902226.
    PubMed     Abstract available


  110. ROSEN CJ, Ingelfinger JR
    Traveling down the Long Road to Type 1 Diabetes Mellitus Prevention.
    N Engl J Med. 2019 Jun 9. doi: 10.1056/NEJMe1907458.
    PubMed    


  111. PITTAS AG, Dawson-Hughes B, Sheehan P, Ware JH, et al
    Vitamin D Supplementation and Prevention of Type 2 Diabetes.
    N Engl J Med. 2019 Jun 7. doi: 10.1056/NEJMoa1900906.
    PubMed     Abstract available


  112. WEXLER DJ
    D2d - No Defense against Diabetes.
    N Engl J Med. 2019 Jun 7. doi: 10.1056/NEJMe1906815.
    PubMed    


  113. LIPSKA KJ, Laiteerapong N
    Lack of Glycemic Legacy Effects in the Veterans Affairs Diabetes Trial.
    N Engl J Med. 2019;380:2266-2267.
    PubMed    


  114. REAVEN PD, Emanuele NV, Wiitala WL, Bahn GD, et al
    Intensive Glucose Control in Patients with Type 2 Diabetes - 15-Year Follow-up.
    N Engl J Med. 2019;380:2215-2224.
    PubMed     Abstract available


    May 2019
  115. INGE TH, Courcoulas AP, Jenkins TM, Michalsky MP, et al
    Five-Year Outcomes of Gastric Bypass in Adolescents as Compared with Adults.
    N Engl J Med. 2019;380:2136-2145.
    PubMed     Abstract available


  116. WIVIOTT SD, Raz I, Sabatine MS
    Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Reply.
    N Engl J Med. 2019;380:1881-1882.
    PubMed    


  117. AKINCI B
    Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2019;380:1881.
    PubMed    


  118. BAGLIONI P
    Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2019;380:1880-1881.
    PubMed    


    April 2019
  119. TAMBORLANE WV, Barrientos-Perez M, Fainberg U, Frimer-Larsen H, et al
    Liraglutide in Children and Adolescents with Type 2 Diabetes.
    N Engl J Med. 2019 Apr 28. doi: 10.1056/NEJMoa1903822.
    PubMed     Abstract available


  120. ROGERS KK
    Diabetes and Disclosure.
    N Engl J Med. 2019;380:1495-1497.
    PubMed    


  121. INGELFINGER JR, Rosen CJ
    Clinical Credence - SGLT2 Inhibitors, Diabetes, and Chronic Kidney Disease.
    N Engl J Med. 2019 Apr 14. doi: 10.1056/NEJMe1904740.
    PubMed    


  122. PERKOVIC V, Jardine MJ, Neal B, Bompoint S, et al
    Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
    N Engl J Med. 2019 Apr 14. doi: 10.1056/NEJMoa1811744.
    PubMed     Abstract available


    March 2019
  123. FERENCE BA, Ray KK, Catapano AL, Ference TB, et al
    Mendelian Randomization Study of ACLY and Cardiovascular Disease.
    N Engl J Med. 2019;380:1033-1042.
    PubMed     Abstract available


    February 2019
  124. RIDKER PM, Everett BM, Pradhan A, MacFadyen JG, et al
    Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
    N Engl J Med. 2019;380:752-762.
    PubMed     Abstract available


    January 2019
  125. KARANDINOS G, Bourgois P
    The Structural Violence of Hyperincarceration - A 44-Year-Old Man with Back Pain.
    N Engl J Med. 2019;380:205-209.
    PubMed    


    December 2018
  126. RAWSHANI A, Rawshani A, Gudbjornsdottir S
    Smoking and Other Risk Factors in Type 2 Diabetes.
    N Engl J Med. 2018;379:2575.
    PubMed    


  127. HU Y, Hu FB, Sun Q
    Smoking and Other Risk Factors in Type 2 Diabetes.
    N Engl J Med. 2018;379:2574-2575.
    PubMed    


  128. KANNT A
    Smoking and Other Risk Factors in Type 2 Diabetes.
    N Engl J Med. 2018;379:2574.
    PubMed    


  129. MANSI IA
    Smoking and Other Risk Factors in Type 2 Diabetes.
    N Engl J Med. 2018;379:2573-2574.
    PubMed    


  130. FAN T, Yang S, Geng Q
    Smoking and Other Risk Factors in Type 2 Diabetes.
    N Engl J Med. 2018;379:2573.
    PubMed    


  131. ANKER MS, Kalantar-Zadeh K, Doehner W
    Smoking and Other Risk Factors in Type 2 Diabetes.
    N Engl J Med. 2018;379:2572-2573.
    PubMed    



  132. Smoking and Other Risk Factors in Type 2 Diabetes.
    N Engl J Med. 2018;379:2572-2575.
    PubMed    


    November 2018
  133. MORA CARPIO AL, Stempel JM
    Pneumococcal Bacteremia and Meningitis.
    N Engl J Med. 2018;379:2063.
    PubMed    


  134. MARCHAND L
    Closed-Loop Insulin for Glycemic Control in Noncritical Care.
    N Engl J Med. 2018;379:1970.
    PubMed    


  135. LAL A, Katta SR, Trivedi N
    Closed-Loop Insulin for Glycemic Control in Noncritical Care.
    N Engl J Med. 2018;379:1970.
    PubMed    


  136. BALLY L, Thabit H, Hovorka R
    Closed-Loop Insulin for Glycemic Control in Noncritical Care.
    N Engl J Med. 2018;379:1970-1971.
    PubMed    


  137. WIVIOTT SD, Raz I, Bonaca MP, Mosenzon O, et al
    Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2018 Nov 10. doi: 10.1056/NEJMoa1812389.
    PubMed     Abstract available


  138. MEKAHLI D, Jouret F
    Copeptin in the Diagnosis of Diabetes Insipidus.
    N Engl J Med. 2018;379:1784-5.
    PubMed    


  139. ROBERTSON GL
    Copeptin in the Diagnosis of Diabetes Insipidus.
    N Engl J Med. 2018;379:1784.
    PubMed    


  140. SPITAL A
    Copeptin in the Diagnosis of Diabetes Insipidus.
    N Engl J Med. 2018;379:1784.
    PubMed    



  141. Copeptin in the Diagnosis of Diabetes Insipidus.
    N Engl J Med. 2018;379:1784-1786.
    PubMed    


  142. DOWNING NS, McMullan CJ, Rennke HG, Levy BD, et al
    Complements from the Lung.
    N Engl J Med. 2018;379:1767-1773.
    PubMed    


    September 2018

  143. Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.
    N Engl J Med. 2018;379:1181-1184.
    PubMed    


  144. RUSSELL MJ, Kanthimathinathan HK
    Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.
    N Engl J Med. 2018;379:1183.
    PubMed    


  145. WHITE PC
    Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.
    N Engl J Med. 2018;379:1182-3.
    PubMed    


  146. KAMEL KS, Carlotti APCP, Halperin ML
    Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.
    N Engl J Med. 2018;379:1181-2.
    PubMed    


    August 2018

  147. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
    N Engl J Med. 2018 Aug 26. doi: 10.1056/NEJMoa1804989.
    PubMed     Abstract available



  148. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.
    N Engl J Med. 2018 Aug 26. doi: 10.1056/NEJMoa1804988.
    PubMed     Abstract available


  149. BOHULA EA, Wiviott SD, McGuire DK, Inzucchi SE, et al
    Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.
    N Engl J Med. 2018 Aug 26. doi: 10.1056/NEJMoa1808721.
    PubMed     Abstract available


  150. TRIPATHY K
    Asteroid Hyalosis.
    N Engl J Med. 2018;379:e12.
    PubMed    


  151. SCHROEDER SA
    Heavier but Healthier - Diabetes and Smoking Cessation.
    N Engl J Med. 2018;379:684-685.
    PubMed    


  152. HU Y, Zong G, Liu G, Wang M, et al
    Smoking Cessation, Weight Change, Type 2 Diabetes, and Mortality.
    N Engl J Med. 2018;379:623-632.
    PubMed     Abstract available


  153. RAWSHANI A, Rawshani A, Franzen S, Sattar N, et al
    Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
    N Engl J Med. 2018;379:633-644.
    PubMed     Abstract available


  154. BALLY L, Thabit H, Hartnell S, Andereggen E, et al
    Closed-Loop Insulin Delivery for Glycemic Control in Noncritical Care.
    N Engl J Med. 2018;379:547-556.
    PubMed     Abstract available


  155. FENSKE W, Refardt J, Chifu I, Schnyder I, et al
    A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus.
    N Engl J Med. 2018;379:428-439.
    PubMed     Abstract available


  156. ROSEN CJ, Ingelfinger JR
    A Reliable Diagnostic Test for Hypotonic Polyuria.
    N Engl J Med. 2018;379:483-484.
    PubMed    


    June 2018
  157. CAN B, Can B
    Change in Overweight from Childhood to Early Adulthood and Risk of Type 2 Diabetes.
    N Engl J Med. 2018;378:2537.
    PubMed    


  158. CADWELL JB, Shukla AP
    Change in Overweight from Childhood to Early Adulthood and Risk of Type 2 Diabetes.
    N Engl J Med. 2018;378:2537.
    PubMed    



  159. Change in Overweight from Childhood to Early Adulthood and Risk of Type 2 Diabetes.
    N Engl J Med. 2018;378:2537-2538.
    PubMed    


  160. SPERLING MA
    Fluid Composition, Infusion Rate, and Brain Injury in Diabetic Ketoacidosis.
    N Engl J Med. 2018;378:2336-2338.
    PubMed    


  161. KUPPERMANN N, Ghetti S, Schunk JE, Stoner MJ, et al
    Clinical Trial of Fluid Infusion Rates for Pediatric Diabetic Ketoacidosis.
    N Engl J Med. 2018;378:2275-2287.
    PubMed     Abstract available


    April 2018
  162. BJERREGAARD LG, Jensen BW, Angquist L, Osler M, et al
    Change in Overweight from Childhood to Early Adulthood and Risk of Type 2 Diabetes.
    N Engl J Med. 2018;378:1302-1312.
    PubMed     Abstract available


    March 2018
  163. HUSEBYE ES, Anderson MS, Kampe O
    Autoimmune Polyendocrine Syndromes.
    N Engl J Med. 2018;378:1132-1141.
    PubMed    


  164. PAWAR AS, Kattah AG
    Lithium-Induced Nephropathy.
    N Engl J Med. 2018;378:1042.
    PubMed    


  165. KHOO TK, Olson KM
    Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
    N Engl J Med. 2018;378:967.
    PubMed    


  166. DOUMAS M, Imprialos KP, Stavropoulos K
    Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
    N Engl J Med. 2018;378:967.
    PubMed    


  167. CONTE C, Secchi A, Napoli N
    Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
    N Engl J Med. 2018;378:966.
    PubMed    


  168. GOGTAY NJ, Bose D, Thatte UM
    Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
    N Engl J Med. 2018;378:966.
    PubMed    



  169. Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
    N Engl J Med. 2018;378:966-968.
    PubMed    


    February 2018
  170. FLYNN JT
    ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.
    N Engl J Med. 2018;378:580.
    PubMed    


  171. MEI ZB, Xiao Y
    ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.
    N Engl J Med. 2018;378:579.
    PubMed    


  172. JONNALAGADDA VG, Metety VK
    ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.
    N Engl J Med. 2018;378:579.
    PubMed    



  173. ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.
    N Engl J Med. 2018;378:579-581.
    PubMed    


    January 2018
  174. AGARWAL A
    Evaluation and Management of Lower-Extremity Ulcers.
    N Engl J Med. 2018;378:302.
    PubMed    


  175. CEREDA E
    Evaluation and Management of Lower-Extremity Ulcers.
    N Engl J Med. 2018;378:301-2.
    PubMed    


  176. DI BELLA S, Monticelli J, Luzzati R
    Evaluation and Management of Lower-Extremity Ulcers.
    N Engl J Med. 2018;378:301.
    PubMed    


    December 2017
  177. IMPRIALOS KP, Stavropoulos K, Doumas M
    Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2502.
    PubMed    


  178. HOLMAN RR, Bethel MA, Hernandez AF
    Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2502.
    PubMed    


    November 2017
  179. THORNTON SN, Regnault V, Lacolley P
    Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2196-7.
    PubMed    


  180. IMPRIALOS KP, Stavropoulos K, Doumas M
    Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2196.
    PubMed    


  181. GULLI G
    Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2195-6.
    PubMed    


  182. TONNEIJCK L, van Raalte DH, Muskiet MHA
    Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2195.
    PubMed    



  183. Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2195-2199.
    PubMed    


  184. DE BOER IH
    Liraglutide and Renal Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017;377:2198.
    PubMed    



  185. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    N Engl J Med. 2017;377:2097-2099.
    PubMed    


  186. RAJAGOPALAN S, Brook R
    Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    N Engl J Med. 2017;377:2098-9.
    PubMed    


  187. FERNANDEZBALSELLS MM, Sojo-Vega L, Ricart-Engel W
    Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    N Engl J Med. 2017;377:2098.
    PubMed    


  188. BAGLIONI P
    Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    N Engl J Med. 2017;377:2097-8.
    PubMed    


  189. PERFETTI R
    Safety of Degludec versus Glargine in Type 2 Diabetes.
    N Engl J Med. 2017;377:1995.
    PubMed    


  190. TAYEK JA, Danese PNN, Smith MS
    Safety of Degludec versus Glargine in Type 2 Diabetes.
    N Engl J Med. 2017;377:1994-5.
    PubMed    


  191. OGUNSAKIN AA, Jain N, Dagogo-Jack S
    Safety of Degludec versus Glargine in Type 2 Diabetes.
    N Engl J Med. 2017;377:1994.
    PubMed    



  192. Safety of Degludec versus Glargine in Type 2 Diabetes.
    N Engl J Med. 2017;377:1995-1996.
    PubMed    


  193. MARCOVECCHIO ML, Chiesa ST, Bond S, Daneman D, et al
    ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes.
    N Engl J Med. 2017;377:1733-1745.
    PubMed     Abstract available


    October 2017
  194. MATSUO T, Ishii N
    Acute Esophageal Necrosis.
    N Engl J Med. 2017;377:1378.
    PubMed    


    September 2017
  195. ADAMS TD, Davidson LE, Litwin SE, Kim J, et al
    Weight and Metabolic Outcomes 12 Years after Gastric Bypass.
    N Engl J Med. 2017;377:1143-1155.
    PubMed     Abstract available


  196. HOLMAN RR, Bethel MA, Mentz RJ, Thompson VP, et al
    Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
    N Engl J Med. 2017 Sep 14. doi: 10.1056/NEJMoa1612917.
    PubMed     Abstract available


  197. GARG SK, Henry RR, Banks P, Buse JB, et al
    Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
    N Engl J Med. 2017 Sep 13. doi: 10.1056/NEJMoa1708337.
    PubMed     Abstract available


  198. NATHAN DM
    Adjunctive Treatments for Type 1 Diabetes.
    N Engl J Med. 2017 Sep 13. doi: 10.1056/NEJMe1711296.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: